The Expression of Vasoactive Intestinal Peptide Receptor 1 Is
                    Negatively Modulated by MicroRNA 525-5p by Cocco, Elisa et al.
The Expression of Vasoactive Intestinal Peptide Receptor









1Department of Biology and Biotechnology ‘‘Charles Darwin’’, Sapienza University, Rome, Italy, 2Department of Cellular Biotechnology and Hematology, Sapienza
University, Rome, Italy
Abstract
Background: The human Vasoactive Intestinal Peptide (VIP) is a neurokine with effects on the immune system where it is
involved in promoting tolerance. In this context, one of its receptors, VPAC1, has been found to be down-modulated in cells
of the immune network in response to activating stimuli. In particular, the bacterial liposaccaride (LPS), a strong activator of
the innate immune system, induces a rapid decrease of VPAC1 expression in monocytes and this event correlates with
polymorphisms in the 39-UTR of the gene.
Methodology/Principal Findings: MicroRNA 525-5p, having as putative target the 39-UTR region of VPAC1, has been
analysed for its expression in monocytes and for its role in down-modulating VPAC1 expression. We report here that miR-
525-5p is promptly up-regulated in LPS-treated monocytes. This microRNA, when co-transfected in 293T cells together with
a construct containing the 39-UTR of the VPAC1 gene, significantly reduced the luciferase activity in a standard expression
assay. The U937 cell line as well as primary monocytes enforced to express miR-525-5p, both down-modulate VPAC1
expression at similar extent.
Conclusions/Significance: Our results show that the response to an inflammatory stimulus elicits in monocytes a rapid
increase of miR-525-5p that targets a signaling pathway involved in the control of the immune homeostasis.
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Introduction
The human Vasoactive Intestinal Peptide (VIP) is expressed and
secreted by neurones innervating primary and secondary immune
organs, and is involved in smooth muscle relaxation, exocrine and
endocrine secretion, and water and ion flux in lung and intestinal
epithelia [1–4]. VIP has also a strong anti-inflammatory effects in
several models of chronic and immune-mediated inflammatory
diseases [5–10]. VIP signals through three type II, G-coupled
receptors, PAC1, VPAC1 and VPAC2, triggering a cascade of
intracellular events that differ depending on cell and receptor types
[11]. VPAC1 is ubiquitous and highly conserved through species
[12]. The down-modulation of the VPAC1 has been described in
response to activating stimuli in cells of the immune system [13].
This has been interpreted as a transient switching off of the
regulatory pathway mediated by VIP that counterbalances the
inflammatory signals. Indeed VIP can modulate the production of
some inflammatory cytokines and chemokines and therefore acts
as an important player in orchestrating the inflammatory response
[14,15]. Furthermore, VIP has been shown to induce human
tolerogenic DCs that, in turn, promote regulatory T cells [16,17].
Therefore, VIP signalling might play a role in dysregulating the
immune system leading to autoimmune diseases. Accordingly, a
deficient expression of one of its receptors, VPAC1, has been
reported in patients with Rheumatoid Arthritis and this appeared
to correlate with polymorphisms at the 39-UTR of the gene [18].
We have also recently described how LPS treatment can induce a
down-modulation of the VPAC1 in monocytes whose kinetics also
correlated with variations at 39-UTR of the gene [19], suggesting a
contribution by this region to VPAC1 tuning.
MicroRNAs are a well-established class of small (22 nucleotides)
endogenous noncoding RNAs that influence the stability and
translation of messenger RNAs. The mature microRNAs are
processed from a 70 nucleotide long precursors (pre-miRNA)
exported from the nucleus, processed through the action of the
cytoplasmic enzyme Dicer, after which the mature miRNA is
loaded into the RNA-induced silencing complex (RISC). The
RISC complex is guided to the 39-untranslated complementary
region (39-UTR) of the target RNAs. The matching is imperfect
and the so-called ‘‘seed region’’ (2–8 nucleotide) is most important
for target recognition and silencing. The recognition of the target
sequence can induce inhibition of the translation and destabiliza-
tion of the target RNA [20–23]. More and more reports are
involving the activity of microRNAs in the modulation of immune
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autoimmune diseases [24–29]. Having shown that the kinetics of
VPAC1 down-regulation in LPS-treated monocytes correlates in
particular with SNP rs896 in the 39-UTR of the VPAC1 gene, we
searched for microRNAs having as putative target a sequence that
harbors or is close to SNP rs896. MiR-525-5p (MI0003152),
mapping in chromosome 19 and showing a sequence partially
complementary to a region contiguous to rs896, appeared as the
best candidate. We show here that miR-525-5p is upregulated in
peripheral blood monocytes upon LPS stimulation and that its
enforced expression causes a significant reduction of the VPAC1.
Results
MicroRNA-525-5p is predicted to target a region of
VPAC1 39-UTR and it is upregulated in LPS-treated
monocytes
According to the observation that SNP rs896 mapping at 39-
UTR of VPAC1 gene correlates with a reduced expression of
VPAC1 mRNA and protein in LPS-treated monocytes [19], an
on-line search in the miRgen database (http://www.diana.pcbi.
upenn.edu/miRGen.html) for microRNAs having as putative
target site the region encompassing or close to rs896, was
performed. Among the 18 microRNAs putatively targeting the
39-UTR of VPAC1, miR-525-5p fulfilled this requirement. This
prompted us to investigate whether miR-525-5p was expressed in
monocytes and whether it was modulated by LPS and/or other
stimuli known to activate monocytes. Figure 1 reports the
quantitative RT-PCR specific for miR-525-5p following treatment
of monocytes from three different individuals with Escherichia coli
liposaccharide (LPS) from two different serotypes: 055:B5
(0.05 mg/ml) and 026:B6 (0.05 mg/ml); PMA (5 nM), CoCl2
(20 mg/ml) and bacterial lipoprotein (LP) (0.05 mg/ml) after 1 h
and 9 h treatment. Interestingly, miR-525-5p was found to be
expressed, although at low level, in the untreated monocytes.
However, its expression was rapidly upmodulated by LPS
treatment. Lipoprotein was also inducing a similar miR-525-5p
upregulation (Figure 1, monocytes RU) whereas CoCl2 and PMA
had no or a negligible effect (Figure 1, monocytes RU, NE and
MA). To confirm the effect of LPS on miR525-5p and to further
analyze the individual variability shown in Figure 1 in the
magnitude of the response to LPS treatment, monocytes from
eight additional healthy subjects were also treated with LPS
(055:B5 serotype) for 1 h, 9 h, and, when possible, 20 h
(Figure 2A). As expected, upon LPS treatment, miR-525-5p
expression was promptly induced. The amount and the kinetics of
its upregulation varied from one subject to the other: in some
cases, the expression increased up to 40 folds (C,H), in some others
only few folds (A,F,G); in most of them the highest level was
reached already after one hour from LPS addition (C,D,F,G,H), in
others the kinetics was slower (B,E). However, in all of them, LPS
treatment induced a clear-cut increase in the miR-525-5p
intracellular level. In the four cases in which the analysis could
be performed at 20 hours time-point, miR-525-5p was reduced
towards the background level, indicating a short time range in
which its functional effects can be produced. In parallel, the
amount of the VPAC1 mRNA was analysed and found to be
deeply down-modulated by LPS in all subjects but E and F, in
which cases the reduction was less pronounced (Figure 2B).
It is known that treatment of monocytes with LPS induces a
strong inflammatory response involving the NF-kB and the MEK-
ERK1/2 pathways and leading to the production of pro-
inflammatory cytokines such as TNF-alpha [30–31]. To investi-
gate whether these two pathways were also controlling the miR-
Figure 1. Effect of different stimuli on miR-525-5p expression in human monocytes. Monocytes from three different donors were used to
analyze the effect of LPS, lipoprotein, PMA and CoCl2 on miR-525-5p expression. (A) Monocytes RU were stimulated with 0.05 mg/ml of LPS from E coli
055:B5; 0.05 mg/ml lipoprotein (LP: Pam2CSK4); 5 nM PMA or 0.05 mg/ml of LPS from E coli 026:B6 for 1 h or 9 h. Relative gene expression in
stimulated cells were compared with untreated cells (UNT), which are set to 1. (B, C) Monocyte NE and MA were stimulated with 0.05 mg/ml LPS (from
Escherichia coli 055:B), 5 nM PMA and 20 mg/ml CoCl2 for 1 h and 9 h. UNT was set to 1.
doi:10.1371/journal.pone.0012067.g001
VPAC1 and miR525-5p
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targeting respectively NF-kB [32] and JNK [33], were used in
combination with LPS and the expression of miR-525-5p as well
as TNF alpha was evaluated in monocytes from two different
donors (Figure 3). The data show that, in both cases, TPCK as
well as SP600125 inhibitors equally impair the expression of miR-
525-5p and TNF-alpha.
VPAC1 39-UTR is a target for miR-525-5p
The induction of miR-525-5p expression in LPS-treated
monocytes, prompted us to verify whether the VPAC1 39-UTR
could be indeed a target for miR-525-5p. A reporter construct was
then generated in the vector pGL3 that contains the SV40
promoter driving the expression of a mRNA encoding the firefly
luciferase (Figure 4). Two constructs of 3-’UTR of VPAC1
(carrying the haplotypes containing C or T at SNP rs896, named
respectively VPAC1-C and VPAC1-T) were cloned downstream
the luciferase gene and transfected into 293T cells together with
mimic hsa-miR-525-5p or negative-control mimic and pRL-TK to
normalize transfection. As further control, a reporter construct
with a three nucleotide mutation in the predicted seed region in
the VPAC1 39-UTR was also generated (Figure 4). Twenty-four
hours after transfection, the cells were harvested and assayed for
luciferase expression. For both VPAC1 constructs, a comparable
repression of luciferase activity ranging around 35%, was observed
in cells transfected with miR-525-5p compared to those transfect-
ed with the negative control (scrambled) (Figure 5, histograms 1 vs
2 and 3 vs 4; p=0.007). The mutation clearly abolished the effect
of miR-525-5p in down-modulating the luciferase activity
(Figure 5, histograms 5–8). The small difference between the
mutated constructs VPAC1-C and VPAC1-T was not significant.
Taken together, these results indicated that miR-525-5p can
interfere with luciferase mRNA translation via direct interaction
with the VPAC1 39-UTR.
MiR-525-5p affects the expression of VPAC1 protein in
U937 cell line as well as in human monocytes
Each miR can have hundreds of targets and the balance between
the amount of that specific miR and the relative abundance of the
targetmRNAsinfluencesthefunctionaloutcome.Toverifywhether
VPAC1 protein expression was indeed regulated by miR-525-5p in
a more physiological setting, U937 cell line, in which miR525-5p
was not expressed but into which hsa-miR-525-5p was efficiently
transfected, were harvested at different times and analysed for
VPAC1.Figure6showsthe resultsofthe westernblot analysis.After
24 h, no difference in the level of expression of VPAC1 protein was
detectable. However, after 48 h, VPAC1 protein was clearly
reduced and after 72 h was still lower than the control. Accordingly,
48 h time point was chosentostatisticallyevaluatetheeffect ofmiR-
525-5p enforced expression on VPAC1 in U937 cell line as well as
primarymonocytes. The experiment was repeated furtherfive times
using the U937 cell line (Figure 7A), and a reduction of 34% of
VPAC1 protein level was again observed (p,0.02). VPAC1 mRNA
level was also affected showing a reduction of about 40% (p,0.02)
Figure 2. Increased expression of miR-525-5p in LPS-treated monocytes. (A): Relative RT-PCR of miR-525 performed in monocytes purified
from 8 subjects (A–H) and unstimulated (0 h) or stimulated with LPS from E coli 055:B (0.05 mg/ml) for 1 h, 9 h and 20 h (only for subjects C, D, G and
H). Results were normalized to 18S expression levels. (B): corresponding levels of VPAC1 mRNA for each subject are reported. Results were normalized
to GAPDH expression levels. AU: arbitrary units.
doi:10.1371/journal.pone.0012067.g002
VPAC1 and miR525-5p
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the enforced expression of miR-525-5p in primary monocytes.
CD14-positive cells isolated from 7 healthy donors were transiently
transfectedwith miR-525-5p or negative controlmiRand harvested
after 48 h. Although the level of VPAC1 expression in each subject
was extremely variable, probably depending on the genetic
background or on the level of activation/differentiation of the
monocytes, the enforced expression of miR-525-5p led to a
consistent reduction of VPAC1 protein compared to the miR
control (p,0.02) (Figure 8). This was not paralleled, as in the
continuous cell line, by a comparable down-modulation of VPAC1
mRNA, which was variable and not significantly different between
monocytes treated with the miR-control or the miR-525-5p (not
shown).
Discussion
Recent research has involved miRNAs in the regulation of
innate and adaptative immune responses as well as in the
inflammatory networks in various cell and tissue types [29,34–
37]. VIP is known to play a relevant role in controlling the
immune response through the signalling of its receptors. In
particular, VPAC1 gene has been shown to be down-modulated in
cells of the immune system after activation [13,19]. We
investigated here whether microRNAs play a role in the LPS-
mediated VPAC1 down-modulation in peripheral blood mono-
cytes. Any given microRNA may regulate hundreds of different
targets at different spatial-temporal settings [38,39] and each one
needs to be experimentally validated. We focused our studies on
miR-525-5p because its target sequence in the VPAC1 mRNA
was next to SNP rs896, that was found to correlate with the
kinetics of VPAC1 mRNA down-modulation and maps within a
stretch of AT (TTTTT/CAAA) where the T/C substitution could
modify the secondary structure of the mRNA. Therefore, it was
interesting to assess whether SNP rs896, mapping just upstream
miR-525-5p target sequence, could influence the binding of this
microRNA. In the experimental settings used in this study, we
were not able to highlight any significant difference in targeting
the two sequences by miR-525-5p. However, there are surprisingly
few studies reporting a differential effect of miRNAs targeting
Figure 3. Effect of LPS inhibitors on miR-525 expression in monocytes. Monocytes NE and ME were treated with 0.05 mg/ml of LPS from E.
coli 055:B and with 50 mM of SP600125 or 25 mM of TPCK. Total RNA was purified from the respective cell pellets and analyzed by qRT-PCR for the
expression of miR-525-5p (A) or TNF-alpha (B). Untreated cells were set to 1. Nd: not done.
doi:10.1371/journal.pone.0012067.g003
Figure 4. The predicted miR-525-5p target site located in the VPAC1 39-UTR. Schematic representation of the expression vector pGL3-
Promoter containing the VPAC1 39-UTR. In detail, the target site of miR-525-5p; the arrow indicates SNP rs896 (C/T). The rectangle highlights the
mutated bases in the seed region.
doi:10.1371/journal.pone.0012067.g004
VPAC1 and miR525-5p
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harbour a considerable number of SNPs [40,41]. This might be
due to technical limitations that do not allow a confident fine
tuning of the system in which the ratio microRNA-target is crucial
and difficult to quantify in its final combination. Therefore,
although we could not see any significant difference in targeting
the two sequences by miR-525-5p, this does not exclude that it
might be relevant in physiological conditions, especially in those
Figure 5. MiR-525-5p inhibits the reporter gene activity. 293T cells were transfected with VPAC1-C and VPAC1-T constructs, harbouring the
two alternative 39-UTR haplotypes or the respective mutated construct and 40 mM of mimic 525-5p RNA or 40 mM of the mimic negative control (SC).
Twenty-four hours post transfection, cell were assayed for Firefly luciferase activity and normalized to Renilla luciferase activity, relative luciferase
activity (AU). Co-transfection of miR525-5p and the two constructs (histograms 1,2 and 3,4) induced the same degree of inhibition of the reporter
activity (35%) (* p=0.007) whereas the mutated constructs showed no significant effect (histograms 5–8). Scrambled-control (SC) level of luciferase
activity was set to 1. Results reported here are the mean6SD of four independent experiments.
doi:10.1371/journal.pone.0012067.g005
Figure 6. U937 cells line transfected with miR-525-5p decrease VPAC1 protein at 48 h. (A) Western blot analysis of VPAC1 in U937 cells
transfected for 24 h, 48 h and 72 h, with 40 mM of miR-525-5p or negative-miR (SC). GAPDH immunoblot was used as loading control. One of three
independent experiments is shown. (B) Densitometric analysis: bars represent the mean6SD of three independent experiments. AU: arbitrary units.
doi:10.1371/journal.pone.0012067.g006
VPAC1 and miR525-5p
PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e12067cases in which the induction of miR-525-5p by LPS is less
pronounced and/or the competion with other targets is higher. In
this context, it is noteworthy that some subjects responded very
effectively to LPS increasing miR-525-5p level manyfold whereas
some others showed a less dramatic upregulation. Such variation
might be due to the genetic background and needs to be further
explored since it might influence the individual response to LPS
and therefore the subsequent inflammatory cascade. However, a
clear cut increase of miR-525-5p was evident in all donors
analysed here. The upregulation at the low LPS dose used here
was temporary since 20 hours after treatment, the level of miR-
525-5p was back or very close to the basal level, suggesting that
there is a narrow window during which miR-525-5p may act on its
targets. This is in agreement with the hypothesis that one of the
tasks of miR-525-5p could be, acting on different targets, to
neutralize the negative signals in the presence of an inflammatory
input. Consequently, its effect must be timely regulated so that,
once the harm stops, the regulatory network can be restored. The
relevance and the specificity of the miR-525-5p upregulation in
the context of the inflammatory response to bacterial stimulation,
is well supported by the observation that only the bacterial
products LPS and, at less extent, LP, were able to induce a
consistent increase of such miR while other compounds known to
activate monocytes such as PMA or CoCl2 do not (Figure 1). Both
the bacterial compounds are ligands for TLR molecules, LP for
TLR2-TLR6 and LPS for TLR4 and their effect is mediated by
NF-kB and MAP kinases pathways [42]. Accordingly, specific
inhibitors of these two ways clearly inhibited miR-525-5p as well
as TNF-alpha upregulation. These data strongly suggest that the
upregulation of miR-525-5p is part of a concerted action that
orchestrates the monocyte response to the bacterial invasion. The
response is effective since the low concentration of LPS (0.05 mg/
ml) used to stimulate monocytes induce a strong upregulation of
miR-525-5p, suggesting a physiological role for this event. We
have shown here that VPAC1, a receptor for a neurokine known
to counteract the inflammatory response, is one of the targets for
Figure 7. The VPAC1 protein level is decreased in U937 cells after 48 h from miR-525-5p transfection. (A) VPAC1 protein level was
evaluated by densitometric analysis of five independent western blots. Bar represents the mean6SD. Scrambled miR was arbitrarily set to 1. VPAC1
protein level was 34% lower in the miR-525-5p transfected cells vs control (* p,0.02). (B) qRT-PCR analysis of VPAC1 mRNA in the same samples as
above (*p,0.02). Scrambled-control (SC) level was set to 1. The error bar represents the mean 6 SD.
doi:10.1371/journal.pone.0012067.g007
VPAC1 and miR525-5p
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transfection, both in the U937 cell line and in the peripheral blood
monocytes. The co-occurrence of the miR-525-5p induction and
of VPAC1 down-modulation already evident few hours after LPS
addition [19], together with the data reported here showing that
VPAC1 is a target for this microRNA, strongly suggests that the
two events co-operate in orchestrating the response of immune
cells to a danger signal. It is likely that the effect of LPS on VPAC1
down-modulation is the result of different events, either transcrip-
tional or post-transcriptional, however this is the first report
showing how the enforced expression of a microRNA determines
its down-tuning. Although there are still several aspects that need
to be explored, i.e. why individuals respond so differently to LPS in
terms of miR-525-5p induction or whether there are other
regulatory mechanisms working in concert with miR-525-5p to
tune down VPAC1 and, eventually, how they interact each other,
nevertheless the data reported here allow to identify a partnership
that is likely to play a role in modulating the native immune
response and, therefore, be a potential therapeutic target.
Materials and Methods
Bioinformatic prediction of miR target site on VPAC1
gene
The miRgen database (http://www.diana.pcbi.upen .edu/
miRGen/v3/miRGen.html) which integrates analysis from Tar-
getScan, Pictar, and Miranda generated a list of 18 predicted
miRNAs targeting the 39-UTR of VPAC1. Among them, miR-
525-5p (GenBank accession no. MI0003152) was chosen fort he
position of its putative target sequence near the SNP rs896.
RNA isolation and miR quantification by RT-PCR Analysis
Total RNA was isolated from monocytes and U937 cell line
using the Trizol reagent (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. RNA quality was
monitored by running the aliquots of each sample in 1% agarose
gel and by spectrophotometric analysis. Subsequently, 10 ng of
total RNA was used to perform reverse transcription using the
TaqManH microRNA assay kit (HSAMIR525 001174, Applied
Biosystems, Foster City, CA, USA) and High-Capacity cDNA
Reverse Trascription kit (Applied Biosystems) according to the
manufacturer’s instructions. VPAC1 transcripts were also evalu-
ated using real-time PCR (HS00270351_m1, Applied Biosystems).
One microgram of total RNA from each sample was reverse
transcribed using random primers of the High Capacity Reverse
Transcription kit. Real-time PCR was performed in ABI PRISM
7300 Sequence Detection Systems (Applied Biosystems) using
TaqManH2X Universal Master Mix (catalog no 4324018, Applied
Biosystems), in a total volume of 20 ml of reaction mixture. Each
sample was assayed in triplicates. The thermal cycling conditions
were set up sequentially as follows: denaturating at 95uC for 10
minutes and 60 cycles of 95uC for 15 seconds and 60uC for 1
minute. The fold change of the microRNA and VPAC1 gene in
the samples was calculated using the 2
2DDCT method. All values
were normalized to endogenous control 18S (HS 99999901-S1,
Applied Biosystems) for miRNA and GAPDH (HS 99999905,
Applied Biosystems) for VPAC1 and were expressed in arbitrary
units.
TNF-a mRNA (HS00174128_m1, Applied Biosystems) expres-
sion was used to evaluated the effect of the pharmacologic
inhibitors on monocytes.
Plasmids
The pGL3 Promoter Vector, a plasmid that express the Firefly
luciferase gene under the control of SV40 promoter and therefore
is constitutively expressed, was purchased from Promega (Madi-
son, WI, USA). The pRL-TK, a plasmid that express Renilla
Luciferase gene under the control of the HSV-TK promoter, was
used as endogenous transfection control.
The human VPAC1 39-UTR (1307–2790 bp of Genebank
accession number NM_004624) was amplified from human cDNA
using PCR and the primers: (forward) 59-gcgcgc tct aga gac act cct
aga gaa cgc ag-39 and (reverse) 59-gcgcgc tct aga ctc cta tcc aga tga
tac atg ag-39. This 1014 bp fragment was cloned into the XbaI site
(underlined in the primers) of pGL3 Promoter Vector downstream
the luciferase gene. The mutated construct was generated by using
PCR-based mutagenesis of the 1014 bp VPAC1 39UTR and
the primers: 59-agtgggttattcgtcagtttttgtttggag-39 and 59ctccaaa-
caaaaactgacgaataacccact-39. This generated a VPAC1-39UTR
with a 3 bp mutation in the predicted miR-525-5p seed region.
The resulting fragment was cloned into the XbaI site of pGL3 as
above. All constructs were checked by DNA sequencing.
Cell cultures and stimulation conditions
Monocytes were purified from peripheral blood of anonymous
donors from the local data banks using the Monocyte isolation kit
(Miltenyi, Bergisch, Gladbach, Germany) according to the
manufacturer’s instructions. Cells were seeded at concentration
of 10
6 cells/ml in RPMI 1640 supplemented with 10% FCS,
2 mM L-glutamine, 25 U/ml penicillin and 25 U/ml streptomy-
Figure 8. MiR-525-5p induces down-modulation of VPAC1
protein in ex vivo transfected monocytes. (A) Western blot analysis
of VPAC1 protein in monocytes transfected with miR525-5p and kept in
culture for 48 h (representative of seven donors analysed). (B) Densito-
metric analysis of western blot. Histograms represent VPAC1 protein level
as mean6SD in monocytes from 7 healthy donors. The decrease was 31%
(*p,0.02). Scrambled-control (SC) was set to 1. AU: arbitrary units.
doi:10.1371/journal.pone.0012067.g008
VPAC1 and miR525-5p
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ncin (all purchased from Gibco, Invitrogen, Carlsbad, CA, USA) in
cell culture plates and treated for 1 h or 9 h with LPS from two
different sources: from E coli 055:B5 (0.05 mg/ml; Sigma-Aldrich,
St Louis, MO, USA) or from E. coli 026:B6 (0.05 mg/ml; Sigma-
Aldrich) or treated with PMA (5 nM; Sigma-Aldrich) or cobalt
chloride (CoCl2, 20 mg/ml; Sigma -Aldrich) or synthetic bacterial
lipoprotein (0,05 mg/ml; Pam2CSK4; InvivoGen, San Diego, CA-
USA). For treatment with pharmacologic inhibitors, human
primary monocytes were incubated for 1 h with SP600125
(50 mM; Calbiochem, Merck KGaA, Darmstadt, Germany) or
TPCK (25 mM; Sigma-Aldrich) in the presence or absence of LPS
(0.05 mg/ml; from E. coli 055:B5, Sigma-Aldrich). 293T cell line
(ATCC cat. CRL-11268) was cultured in DMEM medium,
supplemented with 10% FCS. U937 monocytic leukemic cell line
(ATCC cat. CRL-1593.2) was cultured in RPMI 1640, supple-
mented with 10% FCS. Cells were maintained in a humidified
atmosphere of 7% CO2 at 37uC.
Transfections
The following double-stranded RNAs that mimic mature
miRNA, has-miR-525-5p and miRNAs Negative Control were
obtained from Dharmacon, (Lafayette, USA). The transfection of
293T cells was optimized utilizing JET PEI Polyplus Transfection
Reagent (Polyplus-Transfection, New York, NY, USA). 293T cells
were seeded in 24 wells plate and transfected with the luciferase
reporter constructs described above (300 ng), pRL-TK control
plasmid (5 ng) and the appropriate mimic miRNAs. After 24 h,
cells were lysed with Passive Lysis Buffer (Promega) and the
luciferase activity was determined. U937 cells line and primary
monocytes were transfected with the mimic has-miR-525-5p or
the Negative Control using Lipofectamine 2000 Reagent (Invitro-
gen) according to the manufacturer’s instructions. After the
indicated time from transfection, RNAs and proteins were
extracted for the determination of miR-525 and VPAC1
expression.
Luciferase assay
Luciferase activity was measured using the Dual-Luciferase
Assay kit according to manufacturer’s instructions (Promega) with
a beta-counter luminometer. Relative luciferase activity was
calculated as ratio of the raw Firefly luciferase activity and the
Renilla luciferase activity. All assays were performed in triplicate
in four independent experiments.
Protein extraction and Western blot assay
Protein extracts were prepared from monocytes and U937 cell
line using RIPA buffer (Sigma-Aldrich), and analysed by SDS-
PAGE 12% polyacrilamide gel, blotted on nitrocellulose mem-
brane (GE Healthcare, Piscataway, Nj, USA), and probed o.n.
with rabbit polyclonal antibody anti-VPAC1 (kindly provided by
Dr. K. Freason). The GAPDH signal was used as loading control
(Santa Cruz Biotecnology, Santa Cruz, CA).
Statistical analysis
All data were expressed as mean6SD, the pair comparison was
made, and statistical significance was determined using t-test.
Statistical significance was defined as p,0.05.
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